REG - Hutchmed China Ltd - 2025 Annual Report and Notice of AGM

HUTCHMED (China)Announcement

Today 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260409:nRSI6558Za&default-theme=true

RNS Number : 6558Z  Hutchmed (China) Limited  09 April 2026

2025 Annual Report and Notice of Annual General Meeting

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, April 9, 2026: HUTCHMED
(China) Limited ("HUTCHMED (https://www.hutch-med.com/) ") (Nasdaq/AIM: HCM;
HKEX: 13) today announces that its 2025 Annual Report, together with the
Notice of Annual General Meeting and the Form of Proxy ("AGM Materials"), will
be posted on April 10, 2026 to those shareholders who have elected to receive
the AGM Materials in printed form. The documents can also be accessed from the
HUTCHMED website (www.hutch-med.com (https://www.hutch-med.com/) ).

 

The 2026 Annual General Meeting ("AGM") will be an electronic/hybrid meeting
to be held at 1st Floor, Harbour Grand Kowloon, 20 Tak Fung Street, Hung Hom,
Kowloon, Hong Kong on Tuesday, May 12, 2026 at 4:00 pm Hong Kong Time (9:00 am
London Time), with electronic access through an online platform as detailed in
the AGM Materials.

 

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit:
www.hutch‑med.com (https://www.hutch-med.com/)
 or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/)
.

 

CONTACTS

 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Tim Stamper                            +44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFIFFASLITIIR



            Copyright 2019 Regulatory News Service, all rights reserved